#Sweden #Stockholm #revenue growth #Biopharma #Sobi

Sobi Exceeds Expectations for 2025

Swedish Orphan Biovitrum AB, known as Sobi®, has recently shared its financial results, revealing that both revenue and adjusted EBITA margin for the year 2025 have exceeded earlier forecasts. The company reported a revenue of approximately SEK 28.2 billion, marking a significant growth of about 15% at constant exchange rates. This surge in revenue can be credited to unexpectedly high sales in the fourth quarter, particularly from its products Doptelet, Gamifant, and its haemophilia portfolio.

Detailed Financial Insights

For the fiscal year ending 2025, Sobi's adjusted EBITA margin climbed to around 40% of total revenues, a notable increase that reflects the higher-than-anticipated sales performance. Earlier predictions suggested a lower double-digit percentage growth and an EBITA margin in the mid to high thirties range. This upward trend showcases Sobi's ability to adapt and thrive within a competitive biopharmaceutical landscape.

Analysis of Sales Drivers

The key drivers of this impressive revenue growth include:

• - Doptelet: A treatment for thrombocytopenia, which saw higher-than-expected demand.
• - Gamifant: A therapy targeting a unique set of inflammatory responses, which has gained traction in the latter part of 2025.
• - Haemophilia Portfolio: This essential portfolio continues to be a backbone of Sobi’s offerings, contributing significantly to the overall revenue increase.

Future Projections

Sobi has set the date of its upcoming report for the fourth quarter and full year 2025, which will be released on February 5, 2026. This report is anticipated to provide further insights into the company’s financial health and strategic direction moving forward. Sobi has positioned itself as a leader in the biopharmaceutical sector, focusing on innovative solutions for patients with rare diseases across various global markets, including Europe, North America, and Asia.

Sobi's Commitment to Innovation

With approximately 1,900 employees and listing on NASDAQ Stockholm (STO: SOBI), Sobi’s ongoing commitment to research and innovation remains steadfast. The company’s mission is to unlock the potential of breakthrough therapies, thereby transforming the lives of those who suffer from rare diseases. In 2024, Sobi reported a revenue of SEK 26 billion, indicating a solid growth trajectory leading up to 2025.

As the healthcare industry continues to evolve, Sobi's performance highlights the importance of agility and responsiveness to market dynamics, as evidenced by its proactive strategies that address patient needs effectively. The company's remarkable financial report reaffirms its role as a pivotal player in the biopharmaceutical landscape, demonstrating steadfast growth and progress.

For more detailed updates, Sobi’s investor relations team is available, and further information can be found on their official website and LinkedIn page.